Erythropoietin Alfa: Uses, Dosage, Side Effects | MedexInfo
Labels:
Erythropoiesis-Stimulating Agent
Erythropoietin Alfa
Rx
Generic NameErythropoietin Alfa
Therapeutic ClassErythropoiesis-Stimulating Agent
RouteSC / IV
Max / 24hVaries by indication, usually 40,000 units/week SC
PregnancyUse only if benefit outweighs risk
Indications ▼
Anemia associated with chronic kidney disease (CKD) in adults and children
Prevention and treatment of chemotherapy-induced anemia in cancer patients
Anemia in patients undergoing elective, non-cardiac, non-vascular surgery to reduce the need for transfusion
Anemia in critically ill patients (off-label in select cases)
Mechanism & Pharmacokinetics ▼
Mechanism: Recombinant human erythropoietin stimulates erythroid progenitor cells in the bone marrow, increasing red blood cell production and hemoglobin levels.
Pharmacokinetics: Administered SC or IV. SC absorption slower but longer duration. Half-life: 4–13 hours (SC) and 6–8 hours (IV). Metabolized primarily in the liver and kidneys. Clearance increases with hematocrit.
Dosage & Administration ▼
| Indication | Recommended Dose | Frequency |
|---|---|---|
| CKD (Adult, SC) | 50–100 units/kg | 3x/week |
| CKD (Adult, IV) | 50–100 units/kg | 3x/week |
| Chemotherapy-induced anemia | 150 units/kg SC | 3x/week or 40,000 units once weekly |
| Preoperative anemia (surgery) | 300 units/kg SC | Weekly for 2–3 weeks prior to surgery |
Note: Dose adjustment required based on hemoglobin response and target range. Avoid rapid rise in hemoglobin (>1 g/dL per 2 weeks).
Side Effects ▼
Hypertension
Headache, fatigue
Injection site reactions
Thromboembolic events (rare, especially if hemoglobin rises too quickly)
Seizures (rare)
Contraindications ▼
Uncontrolled hypertension
Hypersensitivity to erythropoietin or any component of the formulation
Pure red cell aplasia (anti-erythropoietin antibodies)
Active malignancy where stimulation of erythropoiesis may be detrimental
Drug Interaction ▼
Androgens: may enhance erythropoietic response
Iron supplementation: often required to maximize response
ACE inhibitors: may reduce erythropoietic response
Antihypertensives: monitor blood pressure as erythropoietin may increase BP
Pregnancy & Lactation ▼
Use only if benefit outweighs risk (Category C)
Excretion in breast milk unknown; caution advised
Clinical / Research Summary ▼
Therapeutic Role: Stimulates red blood cell production in anemia due to CKD, chemotherapy, or surgery, reducing need for transfusions.
Clinical Effectiveness: Increases hemoglobin, reduces transfusion requirements, and improves quality of life in anemic patients.
Safety Profile: Generally well tolerated; hypertension and thromboembolic events are main concerns. Monitor hemoglobin closely.
Current Research: Focus on optimal dosing, cardiovascular outcomes, and minimizing antibody-mediated pure red cell aplasia.
Patient Counseling Points ▼
Monitor blood pressure regularly
Report headache, dizziness, or visual changes
Do not shake or freeze the injection; store as recommended
Follow-up labs: hemoglobin, hematocrit, iron status
Storage & Handling ▼
Store at 2–8°C
Do not freeze
Protect from light
Keep out of reach of children
Brand Names (Bangladesh & Global) ▼
Medical Disclaimer: Educational purpose only. Not a substitute for professional medical advice.
.png)
